THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM

被引：1

作者：

Schroeder, M. ^{[1
]}

Johansen, P. ^{[2
]}

Thompson, G. ^{[1
]}

Willis, M. ^{[3
]}

Neslusan, C. ^{[4
]}

机构：

[1] Hanssen Ciiag UK, High Wycombe, Bucks, England

[2] Swedish Inst Hlth Econ IHE, Lund, Sweden

[3] Swedish Inst Hlth Econ, Lund, Sweden

[4] Janssen Global Serv LLC, Raritan, NJ USA

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.694

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB71

引用

页码：A344 / A344

页数：1

共 50 条

[1] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
Neslusan, C.
Teschemaker, A.
Martin, S.
Willis, M.
Johansen, P.
VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
[2] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
Schroeder, M.
Johansen, P.
Willis, M.
Neslusan, C.
VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
[3] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
DIABETES, 2014, 63 : A310 - A310
[4] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
Pititto, L.
Neslusan, C.
Teschemaker, A. R.
Johansen, P.
Willis, M.
Asano, E.
Puig, A.
VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
[5] The cost-effectiveness of canagliflozin versus sulphonylurea in patients with Type 2 diabetes with inadequate control on metformin monotherapy in the UK
Schroeder, M.
Johansen, P.
Willis, M.
Neslusan, C.
DIABETIC MEDICINE, 2015, 32 : 205 - 205
[6] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) FAILING TO ACHIEVE GLYCAEMIC CONTROL ON METFORMIN MONOTHERAPY IN IRELAND
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
Nuhoho, S.
Worbes-Cerezo, M.
VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
[7] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
Neslusan, Cheryl
Martin, Silas
Teschemaker, Anna
Vo, Lien
Johansen, Pierre
Willis, Michael
DIABETES, 2014, 63 : A309 - A310
[8] THE COST-EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN MONOTHERAPY IN SPAIN
Nielsen, A. T.
Pitcher, A.
Lovato, E.
Schubert, A.
Hemels, M.
Neslusan, C.
Gonzalez, B.
VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
[9] TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
VALUE IN HEALTH, 2015, 18 (03) : A55 - A55
[10] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
Teschemaker, A. R.
Neslusan, C.
Sabapathy, S.
Yoong, K.
Johansen, P.
Willis, M.
VALUE IN HEALTH, 2015, 18 (03) : A62 - A63

← 1 2 3 4 5 →